Collegium PharmaceuticalCOLL
COLL
About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Employees: 357
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
235% more call options, than puts
Call options by funds: $617K | Put options by funds: $184K
23% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 26
1.4% more ownership
Funds ownership: 115.16% [Q4 2024] → 116.56% (+1.4%) [Q1 2025]
3% more capital invested
Capital invested by funds: $1.06B [Q4 2024] → $1.1B (+$30.9M) [Q1 2025]
0% more funds holding
Funds holding: 238 [Q4 2024] → 239 (+1) [Q1 2025]
22% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 97
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$37
27%
upside
Avg. target
$44
52%
upside
High target
$50
71%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Piper Sandler David Amsellem | 27%upside $37 | Neutral Reiterated | 9 May 2025 |
Needham Serge Belanger | 58%upside $46 | Buy Reiterated | 9 Apr 2025 |
HC Wainwright & Co. Oren Livnat | 71%upside $50 | Buy Reiterated | 24 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
Neutral
GlobeNewsWire
1 month ago
Collegium Announces $25 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program.
Neutral
Seeking Alpha
1 month ago
Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:05 PM ET Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2025 Earnings Call May 8, 2025 16:30 ET Company Participants Ian Karp - Head, Investor Relations Vikram Karnani - President and Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants Les Sulewski - Truist Securities Serge Belanger - Needham & Co David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceutical First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded.
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
1 month ago
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
– Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM ® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass.
Positive
Zacks Investment Research
1 month ago
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 month ago
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025.
Positive
Zacks Investment Research
1 month ago
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
GlobeNewsWire
2 months ago
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025.
Charts implemented using Lightweight Charts™